SNDX
Syndax Pharmaceuticals Inc

3,184
Loading...
Loading...
News
all
press releases
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade
The mean of analysts' price targets for Syndax (SNDX) points to an 112.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
A posts fiscal Q3 earnings and revenue beats, with double-digit sales growth and upbeat guidance lifting shares.
Zacks·1mo ago
News Placeholder
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street
These biotech companies’ strategic advancements are setting them up for long-term success.
barchart.com·8mo ago
News Placeholder
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street
The recent advancements in their pipelines imply high growth potential in the coming years.
barchart.com·8mo ago
News Placeholder
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass...
PR Newswire·8mo ago

Latest SNDX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.